These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 22895527

  • 1. Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.
    Li Z, Wu S, Wang J, Li W, Lin Y, Ji C, Xue J, Chen J.
    Int J Mol Med; 2012 Nov; 30(5):1053-60. PubMed ID: 22895527
    [Abstract] [Full Text] [Related]

  • 2. Effect of endosulfan and bisphenol A on the expression of SUMO and UBC9.
    Yarahalli Jayaram V, Baggavalli S, Reddy D, Sistla S, Malempati R.
    Drug Chem Toxicol; 2020 Nov; 43(6):637-644. PubMed ID: 30426790
    [Abstract] [Full Text] [Related]

  • 3. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
    Mascle XH, Lussier-Price M, Cappadocia L, Estephan P, Raiola L, Omichinski JG, Aubry M.
    J Biol Chem; 2013 Dec 20; 288(51):36312-27. PubMed ID: 24174529
    [Abstract] [Full Text] [Related]

  • 4. Noncovalent SUMO-interaction motifs in HIV integrase play important roles in SUMOylation, cofactor binding, and virus replication.
    Zheng Y, Jayappa KD, Ao Z, Qiu X, Su RC, Yao X.
    Virol J; 2019 Apr 02; 16(1):42. PubMed ID: 30940169
    [Abstract] [Full Text] [Related]

  • 5. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
    Wiechmann S, Gärtner A, Kniss A, Stengl A, Behrends C, Rogov VV, Rodriguez MS, Dötsch V, Müller S, Ernst A.
    J Biol Chem; 2017 Sep 15; 292(37):15340-15351. PubMed ID: 28784659
    [Abstract] [Full Text] [Related]

  • 6. Spatiotemporal distribution of SUMOylation components during mouse brain development.
    Hasegawa Y, Yoshida D, Nakamura Y, Sakakibara S.
    J Comp Neurol; 2014 Sep 01; 522(13):3020-36. PubMed ID: 24639124
    [Abstract] [Full Text] [Related]

  • 7. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
    Yang W, Wang L, Roehn G, Pearlstein RD, Ali-Osman F, Pan H, Goldbrunner R, Krantz M, Harms C, Paschen W.
    Cancer Sci; 2013 Jan 01; 104(1):70-7. PubMed ID: 23078246
    [Abstract] [Full Text] [Related]

  • 8. Enhanced detection of in vivo SUMO conjugation by Ubc9 fusion-dependent sumoylation (UFDS).
    Niedenthal R.
    Methods Mol Biol; 2009 Jan 01; 497():63-79. PubMed ID: 19107411
    [Abstract] [Full Text] [Related]

  • 9. SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1.
    Lin CH, Liu SY, Lee EH.
    Oncogene; 2016 Feb 04; 35(5):595-607. PubMed ID: 25867063
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sumoylation of human argonaute 2 at lysine-402 regulates its stability.
    Sahin U, Lapaquette P, Andrieux A, Faure G, Dejean A.
    PLoS One; 2014 Feb 04; 9(7):e102957. PubMed ID: 25036361
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs).
    Wu YC, Roark AA, Bian XL, Wilson VG.
    Virology; 2008 Sep 01; 378(2):329-38. PubMed ID: 18619639
    [Abstract] [Full Text] [Related]

  • 15. Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection.
    Yueh A, Leung J, Bhattacharyya S, Perrone LA, de los Santos K, Pu SY, Goff SP.
    J Virol; 2006 Jan 01; 80(1):342-52. PubMed ID: 16352559
    [Abstract] [Full Text] [Related]

  • 16. A stable chemical SUMO1-Ubc9 conjugate specifically binds as a thioester mimic to the RanBP2-E3 ligase complex.
    Sommer S, Ritterhoff T, Melchior F, Mootz HD.
    Chembiochem; 2015 May 26; 16(8):1183-9. PubMed ID: 25917782
    [Abstract] [Full Text] [Related]

  • 17. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
    Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, Bock C, Kralovics R, Superti-Furga G, Colinge J, Nijman SM, Kubicek S.
    Oncogene; 2015 Jul 26; 34(29):3780-90. PubMed ID: 25263445
    [Abstract] [Full Text] [Related]

  • 18. MEL-18 interacts with HSF2 and the SUMO E2 UBC9 to inhibit HSF2 sumoylation.
    Zhang J, Goodson ML, Hong Y, Sarge KD.
    J Biol Chem; 2008 Mar 21; 283(12):7464-9. PubMed ID: 18211895
    [Abstract] [Full Text] [Related]

  • 19. SUMO Ubc9 enzyme as a viral target.
    Varadaraj A, Mattoscio D, Chiocca S.
    IUBMB Life; 2014 Jan 21; 66(1):27-33. PubMed ID: 24395713
    [Abstract] [Full Text] [Related]

  • 20. Enhanced SUMOylation of proteins containing a SUMO-interacting motif by SUMO-Ubc9 fusion.
    Kim ET, Kim KK, Matunis MJ, Ahn JH.
    Biochem Biophys Res Commun; 2009 Oct 09; 388(1):41-5. PubMed ID: 19635459
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.